Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

Abstract

This prospective clinical trial was designed to assess the impact of adjuvant chemotherapy in women with rapidly proliferating node-negative breast cancer. This group has been predicted to have a 5-year disease-free survival (DFS) of 70% without adjuvant chemotherapy. In this study, 449 women with rapidly proliferating breast cancer (91% measured by S-phase fraction and 9% by histochemistry) received adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) plus tamoxifen for estrogen receptor-positive or progesterone receptor-positive cancer. The 5-year DFS was 90% (+/- 2%) and the 5-year overall survival was 94% (+/- 1%). At a median follow-up of 62 months, the strategy of administering 6 cycles of AC to women with T2 N0 cancer and 3 cycles in those with smaller T1 N0 cancers appeared to eliminate tumor size as a potential prognostic factor. Adjuvant chemotherapy with AC appears effective in reducing recurrence rates for women with rapidly proliferating node-negative breast cancer.

• Authors: Stephen E Jones, Gary Clark, Sherry Koleszar, Gaby Ethington, Robert Mennel, Steven Paulson, Barry Brooks, Ronald Kerr, Claude Denham, Michael Savin, Joanne Blum, Robert Kirby, Marvin Stone, John Pippen, Timothy George, Douglas Orr, Sally Knox, Michael Grant, George Peters, Daniel Savino, Charles Rietz
• Journal: Clinical breast cancer (Clin Breast Cancer) Vol. 3 Issue 2 Pg. 147-52 (Jun 2002) ISSN: 1526-8209 [Print] United States
• PMID: 12123539 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anticarcinogenic Agents
• Antineoplastic Agents
• Tamoxifen
• Doxorubicin
• Cyclophosphamide

Topics

• Adult
• Aged
• Anticarcinogenic Agents (administration & dosage, therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Breast Neoplasms (drug therapy, mortality, pathology)
• Chemotherapy, Adjuvant
• Cyclophosphamide (administration & dosage, therapeutic use)
• Disease-Free Survival
• Doxorubicin (administration & dosage, therapeutic use)
• Female
• Humans
• Lymph Nodes (pathology)
• Middle Aged
• Neoplasm Invasiveness (pathology, prevention & control)
• Prospective Studies
• Survival Rate
• Tamoxifen (administration & dosage, therapeutic use)